Lisa Walters-Hoffert

CIK: 0001711576

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)2 (40.0%)

Derivative conversions

Awards (A)3 (60.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

KPRX

KIORA PHARMACEUTICALS INC

Director

FLUX

Flux Power Holdings, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

KPRX
KIORA PHARMACEUTICALS INC
Jun 10, 2026
Award(A)
Stock Option (right to buy)
Direct
25K shares-
FLUX
Flux Power Holdings, Inc.
May 28, 2026
Exercise(M)
Direct
50K shares-
FLUX
Flux Power Holdings, Inc.
May 28, 2025
Award(A)
Restricted Stock Units
Direct
50K shares-
FLUX
Flux Power Holdings, Inc.
Apr 18, 2025
Exercise(M)
Direct
17.1K shares-
KPRX
KIORA PHARMACEUTICALS INC
Apr 1, 2025
Award(A)
Stock Option (right to buy)
Direct
20K shares-

		Type	Shares	Price		Ownership
Jun 10, 2026	KPRX KIORA PHARMACEUTICALS INC	Award(A) Stock Option (right to buy)	25,000	-	-	Direct
May 28, 2026	FLUX Flux Power Holdings, Inc.	Exercise(M)	50,000	-	$0	Direct
May 28, 2025	FLUX Flux Power Holdings, Inc.	Award(A) Restricted Stock Units	50,000	-	-	Direct
Apr 18, 2025	FLUX Flux Power Holdings, Inc.	Exercise(M)	17,057	-	-	Direct
Apr 1, 2025	KPRX KIORA PHARMACEUTICALS INC	Award(A) Stock Option (right to buy)	20,000	-	-	Direct

1-5 of 5 transactions

About Walters-Hoffert Lisa

Walters-Hoffert Lisa (SEC CIK 0001711576) files insider reports with the SEC as Director of KIORA PHARMACEUTICALS INC (KPRX) and Director of Flux Power Holdings, Inc. (FLUX).

Signal8 holds 4 ownership filings by Walters-Hoffert Lisa, all Form 4s, filed between Apr 2, 2025 and Jun 12, 2026. Those filings report 5 transactions, from Apr 1, 2025 to Jun 10, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Walters-Hoffert Lisa's filings is in VISTA, CA.

Recent filings by Walters-Hoffert Lisa

Jun 10, 2026: Grant or award of KPRX derivative securities (Form 4, code A).
May 28, 2026: Option exercise of FLUX shares (Form 4, code M).
May 28, 2025: Grant or award of FLUX derivative securities (Form 4, code A).
Apr 18, 2025: Option exercise of FLUX shares (Form 4, code M).
Apr 1, 2025: Grant or award of KPRX derivative securities (Form 4, code A).

Other insiders filing for KIORA PHARMACEUTICALS INC (KPRX)

Lane Keith J., Officer
Tosca Melissa, CFO
Strem Brian M., President and CEO
Stengone Carmine N., Director
Shapiro Aron, Director
Parsons Erin, Director

How to read Form 4 transaction codes